Primary central nervous system (CNS) diffuse large B-cell lymphoma (DLBCL) is a subtype of DLBCL with an unfavorable prognosis and a poor response to the treatment. As we know, DLBCL is stratified into germinal center B-cell (GCB)-like and activated B-cell (ABC)-like subtypes with different prognosis according to their gene-expression characteristics. In this study, we analyzed a case series of 77 patients with primary CNS DLBCL. A difference in prognosis of GCB-like and ABC-like subtypes was noticed, but no statistical significance was found. However, significant prognostic value of MYC/BCL2 co-expression was shown. The cases with MYC/BCL2 co-expression did not show any predominance of the 2 subtypes in our cases. Furthermore, patients with MYC/ BCL2 co-expression had significantly worse overall survival for both cell of origin (COO) subtypes. We conjecture that MYC/ BCL2 co-expression is associated with a poorer prognosis and is independent of COO classification. Moreover, the data suggest that MYC/BCL2 co-expression is superior to COO classification assessed by immunohistochemical analysis in patients with primary CNS DLBCL.
INTRODUCTION
Primary central nervous system lymphoma (PCNSL) is a rare and highly invasive malignancy that accounts for 1.5%-3% in all cerebral tumors. The most common type, constituting $80% of the total PCNSL, is diffuse large B cell lymphoma (DLBCL). CNS lymphomas with evidence of systemic disease at the time of presentation are excluded (1) . CNS DLBCL is recognized as a subtype of DLBCL because of the poor prognosis and characteristic genetic features (2) . The International Extranodal Lymphoma Study Group (IELSG) prognostic score has become a useful clinical predictor of survival in patients with PCNSL (3) . Of the variables tested, age of 60 years or younger, Eastern Cooperative Oncology Group Score Performance Status of <2, normal lactate dehydrogenase level, normal cerebrospinal fluid protein concentration, and no involvement of the deep regions of the brain (basal ganglia, corpus callosum, brainstem, or cerebellum) are associated with better survival in univariate and multivariate analyses (3) .
With the cell of origin (COO) concept, DLBCL has been divided into 2 major subtypes with different prognosis according to the "gold standard" method based on gene expression profiling (GEP) of RNA from fresh frozen tissue using microarray technology. The germinal center B-cell (GCB)-like subtype of DLBCL is considered to have a better prognosis than the activated B-cell (ABC)-like subtype (4, 5) . Because of the high prices and strict requirements regarding tissue, routine use of this method is difficult (6) . As a result, some immunohistochemistry-based algorithms have been described, including the Hans, Choi, Visco-Young, and Tally algorithms. Nevertheless, these immunohistochemistry-based methods are not in concordance with the "gold standard," meaning that they are not yet ready to guide clinical care.
DLBCL with translocation of both MYC and BCL2, also known as double-hit lymphoma (DHL), is characterized by its poor response to standard therapy and aggressive clinical course. There is growing interest in the more common "doubleexpressing" lymphomas (DELs), defined as co-expression of 2 oncogenes (MYC and BCL2) based on immunohistochemical staining (7, 8) . More recently, one large multicenter analysis (9) found that the prognostic effects of COO were lost when adjusting for DEL, which suggested that MYC/BCL2 co-expression by immunohistochemical analysis is a more reliable predictor of prognosis than COO in patients with DLBCL.
Most primary CNS DLBCLs possess the ABC immunophenotype, which may explain the poor prognosis of primary CNS DLBCL (10) . Would the prognostic significance of MYC/BCL2 co-expression be superior to the COO concept in primary CNS DLBCL, just like that in DLBCL? In this study, we analyzed the immunohistochemical status of primary CNS DLBCL and tried to find the answer to this question.
MATERIALS AND METHODS

Patients
We retrospectively retrieved and included formalinfixed, paraffin-embedded pretreatment diagnostic biopsy samples from 77 patients with primary CNS DLBCL from January 2005 to December 2015 in the pathology department of Nanjing Jinling Hospital. The chosen patients presented with brain lesions, and no patient had immunodeficiency or extraneural involvement. The clinicopathological information including the patients' age, number of lesions, location, and treatment, was collected. The follow-up data for all 77 patients were collected.
Immunohistochemical Staining and Interpretation
Tissues were fixed in 10% formalin and embedded in paraffin. Sections (3-lm thickness) were stained with hematoxylin and eosin and immunohistochemical analysis was performed. The following antibodies were used: CD10 (56C6, Ready-to-use, Dako, Glostrup, Denmark), BCL6 (PG-B6p, Ready-to-use, Dako), MUM1 (ab133590, 1:100, Abcam, Cambridge, MA), MYC (Y69, 1:100, Abcam), and BCL2 (clone 124, Ready-to-use, Dako). Immunoreaction was performed using the labeled streptavidin-biotin method and overnight incubation. The scores for these antibody staining were estimated visually in 10% increments by 2 pathologists. The cutoff for positivity of CD10, BCL6, and MUM1 was 30% or higher for each, the cutoff was 40% or higher for MYC, and 70% or higher for BCL2, as described (11, 12) . The staining pattern for MYC protein was distinctly nuclear, whereas the staining for BCL2 protein showed a well-defined cytoplasmic staining pattern. Cases were assigned to the GCB group if CD10 was positive. If both BCL6 and CD10 were negative, the case was assigned to the ABC (or nonGCB) subgroup. If CD10 was negative and BCL6 was positive, the group was determined by MUM1: If MUM1 was negative, the case was assigned to the GCB group; if MUM1 was positive, the case was assigned to the ABC group.
Statistical Analysis
Overall survival (OS) was defined as the time from the initial diagnosis to death or the last follow-up. Patients who were alive at the last follow-up were treated as censored. The relationship between clinicopathological characteristics and MYC/BCL2 co-expression was analyzed with v 2 -tests. The association of patients' clinical parameters and COO, MYC/ BCL2 co-expression with the outcomes of the patients was examined with both univariate and multivariate analyses. Kaplan-Meier estimates were used to predict the OS, and comparison was performed using log-rank tests. The effects of the study variables were assessed by multivariate analysis on the basis of a Cox regression model for OS. All analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL) software. The statistical level of significance was defined as a p value of less than. . . .
RESULTS
Clinical and Immunohistochemical Features of Primary CNS DLBCL
The clinical features of 77 patients with primary CNS DLBCL are listed in Table 1 . The median follow-up time for this study cohort was 18 months (from 1 to 115 months). The 3-year OS rate was 47% and 5-year OS rate was 23%. The other clinical features are described in Table 1 . We classified the patients into 2 groups according to treatment method. Forty two (55%) patients were treated with methotrexate (MTX) and 35 (45%) were not. No significantly prognostic value was found in the clinical features including age and involvement of the deep regions of the brain, which were considered to be independent prognostic factors in IELSG prognostic score (Table 1) .
Histological examination showed diffuse large-cell type of morphology in all cases (Fig. 1A) . Immunochemical data showed that 14 patients (18%) were positive for CD10 (Fig.  1B) , 58 (75%) for BCL6 (Fig. 1C) , and 76 (99%) for MUM-1 (Fig. 1D) . As a result, 14 patients (18%) were classified as the GCB subtype and 63 (82%) the ABC subtype (Table 1) . Sixty (78%) were positive for MYC ( Fig. 1E ) and 47 (61%) were positive for BCL2 ( Fig. 1F) with cutoff values of 40% and 70% positive tumor cells for MYC and BCL2, respectively. Thirty-six patients (47%) were positive for both MYC and BCL2 and 6 (8%) were negative for both.
Various clinicopathologic characteristics were compared between primary CNS DLBCL patients with and without double-expression. We also compared the same clinical features between GCB-like and ABC-like subtypes (Table 1) . However, no significant difference was found in the clinical parameters between patients with different MYC/BCL2 expressions and the COO concept, respectively.
Prognostic Value of COO Concept and MYC/BCL2 Protein Co-Expression in Primary CNS DLBCL
As described, the majority of the cases were classified as ABC-like subtype based on the immunohistochemical data. The GCB-like subtype was associated with a longer OS (3 years, 69% vs 42%; p¼ 0.054) than ABC-like cases (Fig. 2) . However, no prognostic value was found with the COO concept when patients were divided into 2 groups according to MTX-based treatment (data not shown).
MYC/BCL2 co-expression in primary CNS DLBCL had a significant adverse impact on patient survival (3-year OS rate, 26%; other patients, 62%; p ¼ 0.0001; Fig. 3 ). In multivariate analysis, DEL remained its prognostic value of OS in patients with primary CNS DLBCL ( Table 2) . When analyzed separately, it showed that patients with MYC expression had a significantly inferior OS rate than patients without MYC expression (p ¼ 0.010; Supplementary Data Fig. S1 ), and the same result was found for BCL2 expression (p ¼ 0.011; Sup plementary Data Fig. S2 ) using a cutoff value of 70%. We also detected the prognostic significance of BCL2 with a cutoff of 50%, which was described in other research (13) , but no significant difference was found in survival between patients with or without BCL2 expression (data not shown). We then excluded the patients with double-expression and found that MYC and BCL2 lost their prognostic value (p ¼ 0.147 and 0.961, respectively). We also evaluated survival in patients treated with and without MTX and found different results. Prognostic significance remained in the DEL group in patients with MTX treatment (p ¼ 0.0001), but not in patients without MTX (p ¼ 0.189). 
MYC/BCL2 Co-Expression Confers an Adverse Prognostic Impact Independent From COO Concept MYC/BCL2 co-expression did not show predominance of any COO subtype in our cases. Of the 36 cases of primary CNS DLBCL with MYC/BCL2 co-expression, 32 (89%) were of the ABC-like type and 4 (11%) were of the GCB-like type. However, there was no significant relationship between double-expression and COO concept, as shown in Table 1 . When analyzing the proteins individually, no association was found between COO concept and protein expression.
We next investigated whether the prognostic significance of the DEL was dependent on the COO subtype. After stratifying all of the patients into GCB and ABC subtypes, those with MYC/BCL2 co-expression had a significantly lower OS rate within both ABC (p ¼ 0.007; Supplementary Data Fig. S5 ). However, we did not expect the OS of patients with ABC-like subtype to be inferior to that of patients with GCBlike subtype in univariate analysis after excluding all cases with MYC/BCL2 co-expression (p ¼ 0.049; Supplementary  Data Fig. S6) .
Finally, we analyzed the prognostic value of the coexpression and COO concept in multivariate analysis. As shown in Table 2 , MYC/BCL2 co-expression remained a strong independent predictor of OS in primary CNS DLBCL (p ¼ 0.003).
DISCUSSION
Primary CNS DLBCL is a rare entity of DLBCL with an inferior prognosis and responses to current treatment regimens. A few articles have described the expression of MYC and BCL2 in primary CNS DLBCL, but none has compared the COO concept and MYC/BCL2 co-expression in this type of tumor. In this study, we analyzed the immunochemical status of MYC, BCL2, and COO concept aiming to find the better prognostic immunochemical combination in primary CNS DLBCL.
The COO concept based on GEP is considered to be a strong prognostic factor in systematic DLBCL, and the COO subtypes have different responses to therapeutic agents (14, 15) . In this study, 77 patients were classified into 2 groups by Hans algorithm, which was raised in 2004 to replicate the COO assignments made with GEP on fresh frozen tissue (11). Meyer et al detected tissue sections from 130 patients with DLBCL using GEP and immunochemical staining and found that Hans algorithm had high concordance with the microarray results and was useful for determination of the COO as defined by GEP (16) . Some research (11, 17, 18) has shown the COO concept to be an important outcome predictor for patients with DLBCL who undergo chemotherapy. However, in recent years, few studies showed that COO defined by immunochemistry could not predict the prognosis of DLBCL, especially in patients who undergo chemotherapy (19, 20) . As in systematic DLBCL, the simplified COO concept using immunochemistry always led to inconsistent results in studies of patients with primary CNS DLBCL. Camilleri-Broet et al noticed that the poor prognosis of primary CNS DLBCL might be partly due to its ABC-like pattern (10) . No statistically significant difference was seen in the OS between the 2 groups in the study of primary CNS DLBCL by Hattab et al (21) , and Gill et al did not detect any adverse effect of ABC-like subtype (22) . In the aforementioned studies, although the survival times were obviously different in the figures, no statistically significant difference was found because of the rarity of GCB-like subtype. Our study included 14 GCB-like cases and 63 ABC-like cases. Although the ABC-like group seemed to have a poorer prognosis, the OS of the 2 groups did not differ significantly (p ¼ 0.054). In addition, when the outcome of MTX-treated and nonMTX-treated patients was compared separately in GCB and ABC groups, no significant differences were found in the survival parameters. We should take into account that the COO concept cannot predict the survival in primary CNS DLBCL.
MYC/BCL2 DHL, recognized as chromosomal breaks involving MYC and BCL2, is a rare disease, representing $3% of all DLBCL cases (9) . They have been associated with resistance or a poor response to therapy and an inferior survival rate in systemic DLBCL . High MYC and/or BCL2 protein expression assessed by immunohistochemistry has also (27) . Furthermore, DHL and DEL are always associated with worse performance status, a greater incidence of stage III/IV diseases, a higher International Prognostic Index, and a higher proliferation index (9, 12, 28) . Research studies regarding the prognosis of DHL and DEL did not come to the same conclusions on systematic DLBCL. In several previous studies, DHL was found to have a poorer prognosis than DEL (9, 13) . However, in a study by Green et al of systematic DLBCL, no significant in OS difference was confirmed when comparing DHL with the DEL group without DHL (12) . Also, in another large-scale investigation, DEL remained a significant predictor of inferior OS (9) . Some studies have examined MYC/BCL2 coexpression and DHL in primary CNS DLBCL. Although MYC protein expression in primary CNS DLBCL significantly exceeded systemic DLBCL (29) , the MYC rearrangement in primary CNS DLBCL was actually similar to that in systematic DLBCL according to previous reports (8% vs 11%), meaning that gene rearrangement was poorly correlated with the protein expression (12, 21, 29) . Therefore, the rarity of MYC rearrangement and the high frequency of MYC overexpression is an arresting phenomenon that may be attributed to other genetic aberrations like MYC mutations or altered regulation of expression. In our study, MYC expression was noted in 78% of the cases. The proportion was similar to that seen by Gill et al (73%) (22) but slightly lower than that seen by Brunn et al (92%) (29) . However, it was still higher than that described in systemic DLBCL ($30%-50%) (9, 13, 24) . BCL2 protein expression and BCL2 abnormality varied in primary CNS DLBCL (56%-92% and 0%-37%, respectively) (29, 30) and the prognostic value of BCL2 expression was also unclear. In Tapia's study, BCL2 positivity was observed in 71% of primary CNS DLBCL cases, but it had no relationship with prognosis (31) . In contrast, another study demonstrated that patients with primary CNS DLBCL and BCL2 overexpression had a significantly poorer OS (32) . BCL2 expression was detected in 61% of cases in our series, which was within the range described previously. The prognosis of BCL2 was also analyzed and its prognostic significance was confirmed. The prognostic value of MYC/BCL2 co-expression in primary CNS DLBCL still does not allow a unified conclusion to be drawn. Gill et al found no prognostic significance of MYC and/or BCL2 expression was found in survival (22) . In contrast, Guo et al found that MYC expression alone and MYC/BCL2 co-expression were significantly associated with outcome in patients with primary CNS DLBCL (33) . In our research, we investigated 77 patients with primary CNS DLBCL and confirmed that MYC/BCL2 co-expression was a prominent prognostic factor in primary CNS DLBCL regardless of COO concept, age, involvement of the deep regions of the brain and treatment. Few studies have examined the effects of MYC/BCL2 co-expression on the curative effect in primary CSN DLBCL. Kim et al found that patients with primary CNS DLBCL with MYC/BCL2 co-expression exhibited worse progression-free survival in the MTX-treated group (32) . The same conclusion was reached in our study. We believe that MYC/BCL2 co-expression is a viable biomarker in patients with primary CNS DLBCL treated with MTX.
Different immunohistochemical scoring and antibodies would make a difference in the results. Kim et al used antibodies against MYC (clone EP121, Cell Marque, Rocklin, CA), BCL2 (clone 124, DAKO, Carpinteria, CA) with cutoff values of 40% or higher for MYC, 30% or higher for BCL2 (32) . The positive percentages were 18.1% and 75%, respectively. Both MYC and BCL2 affected the survival. Gill et al used MYC (clone 9E10, Epitomics Inc., Burlingame, CA) and BCL2 (clone bcl-2/100/D5, predilute, Novocastra, Buffalo Grove, IL), with cutoff values of ! 40% for MYC and !70% for BCL2 (22) . The positive percentages were 73% and 71%, respectively, and neither had an effect on survival. Guo et al used MYC (Clone Y69; Abcam, Shanghai, China) and BCL2 (Clone 124, DAKO) as primary antibodies (33) . The positive percentages were 33.3% and 81.8%, respectively, with cutoff values for positivity of ! 40% for MYC, !30% for BCL2. A prognostic value was found in MYC rather than BCL2. In our research, we used Y69 for MYC and clone 124 for BCL2: 78% of cases were positive for MYC and 61% of cases were positive for BCL2 with cutoff values of 40% and 70% positive tumor cells for MYC and BCL2, respectively. Both MYC and BCL2 had significant impact on survival. We also detected the prognostic significance of BCL2 with a cutoff of 50% but no prognostic value was found.
To the best of our knowledge, this research is the first to compare the prognostic value of MYC/BCL2 doubleexpression and COO subtypes in patients with primary CNS DLBCL. Whether the MYC/BCL2 co-expression is better than the COO concept is still unknown in systematic DLBCL. Recently, some studies proposed that MYC/BCL2 coexpression was an independent predictor of OS in DLBCL patients and was better than the COO concept. Green et al regarded MYC/BCL2 co-expression as an independent predictor in DLBCL with better agreement in immunochemical scoring (12, 34) . Hu et al had findings that agreed with those of previous studies. In their cases, patients with the ABC or GCB subtype of DLBCL had similar prognosis in both the MYC/ BCL2 co-expression group and the other group (9) . MYC/ BCL2 co-expression is the best predictor of prognosis in patients with DLBCL treated with R-CHOP instead of COO classification because the majority of treatment failures after R-CHOP are in co-expression DLBCL (35) . However, the COO concept is a better prognostic factor than MYC/BCL2 co-expression when using the Lymph2Cx assay, an RNAbased digital expression platform (36) . In our series, both the COO concept and MYC/BCL2 co-expression were detected by immunochemistry. The prognostic value of MYC/BCL2 co-expression remained while the COO concept was lost in multivariate analysis, and MYC/BCL2 co-expression was a prognostic factor in both the GCB and ABC subtypes. However, we had not predicted the statistical significance of ABClike subtype when excluding all cases with MYC/BCL2 co-expression, which was at variance with the findings of Hu et al. We tried to explain this phenomenon but failed. We found no connection between the COO concept and adverse prognostic factors in our series. The COO concept may still play a role in the prognosis of patients in some way, or the unexpected result may merely be attributable to the selected cohort. More cases should be incorporated into further study. In summary, MYC/BCL2 co-expression is a reliable and independent prognostic indicator of primary CNS DLBCL, and the predictive value of the COO concept is still indistinct in patients with primary CNS DLBCL. Although the ABClike subtype is considered to be a predictor when excluding all cases with MYC/BCL2 co-expression, the effect of the COO concept in primary CNS DLBCL remains unclear and requires further investigation. Our study has some defects. We did not gather adequate data on the ECOG, lactate dehydrogenase level and normal cerebrospinal fluid protein concentration, as most patients did not undergo those examinations. Our failure to detect the rearrangement of MYC and BCL2 is also an imperfection. As a result, we cannot realize the proportion of double-hit cases in primary CNS DLBCL. Whereas, immunohistochemistry is the most commonly used method in routine work. Our research could also assist pathologists and clinicians in the initial prediction of prognosis and in selection of a therapeutic regimen with a comparatively simple and convenient process. On the basis of the literature and our study, MYC/BCL2 co-expression is better than the COO concept as assessed by immunohistochemistry in patients with primary CNS DLBCL.
